

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma [ID6193]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues have been identified by stakeholders. However, the company noted that multiple myeloma is more common in men, older people (≥ 75 years) and people of African and Caribbean family background.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The committee would consider the higher prevalence of the condition in these groups.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Ross Dent

Date: 14/06/2023